\
&
Contact us
\
&
Contact us
Starts in 2 hours from now
LocationOnline
ProgrammesThis online information day aims to inform (potential) applicants about the destinations and topics included in the NEB Facility part of the Horizon Europe ‘main’ work programme for 2025.
The event will be live streamed on the New European Bauhaus website. No registration is required to follow the live stream. You can however fill out this form by 1 June 2025 to receive a reminder about the event.
Ahead of the event, participants are advised to watch the pre-recorded presentations (soon available) and to send your questions in advance. Questions can be submitted via Sli.do by using #NEBFacilityInfoday25, so that they can be answered fully and in priority during the live event.
More information on this event can be found here.
In addition to this info session a matchmaking event on the 2025 NEB Facility calls will be organized the next day on 5 June 2025. More information can be found here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
